Breast Cancer Clinical Trial
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.
Summary
This research study is designed to evaluate an experimental drug, MEDI4276, in treating breast and stomach (gastric) cancer.
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years.
Histologically or cytologically documented unresectable, locally advanced or metastatic breast cancer or gastric cancer refractory to standard therapy.
For subjects with breast cancer:
Prior treatment with trastuzumab, pertuzumab, and T-DM1, either alone or in combination, is required.
Subjects with a primary tumor that is hormone (estrogen, progesterone, or both) receptor-positive or receptor-negative are eligible.
Prior hormone therapy is allowed, but last dose must be at least 14 days prior to first dose of MEDI4276.
For subjects with gastric cancer:
Prior treatment with a trastuzumab containing chemotherapy regimen is required.
HER2 Positive disease documented as FISH-positive and/or 3+ by IHC on previously collected tumor tissue.
At least one lesion measurable by RECIST Version 1.1.
Exclusion Criteria:
Receipt of any conventional or investigational anticancer treatment within 28 days prior to the first dose of MEDI4276.
History of exposure to the following cumulative doses of anthracyclines:
Doxorubicin or liposomal doxorubicin >350 mg/m².
Epirubicin >530 mg/m².
Mitoxantrone >90 mg/m² and idarubicin > 70 mg/m².
If another anthracycline or more than 1 anthracycline has been used, then the cumulative dose must not exceed the equivalent of 350 mg/m² of doxorubicin.
Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms; or any radiation, surgery or other therapy to control symptoms from brain metastases within 2 months prior to first dose of MEDI4276.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Stanford California, 94305, United States
Sarasota Florida, 34232, United States
Indianapolis Indiana, 46202, United States
Charlotte North Carolina, 28204, United States
Nashville Tennessee, 37203, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.